LIVMARLI Oral Solution

USDailyMed:Maralixibat chloride A05AX04(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-only 1-[4-({4-[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenoxy}methyl)benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane 716313-53-0as salt:228113-66-4 DB16226as salt:DBSALT003196 8007375as salt:8007374 UYB6UOF69Las salt:V78M04F0XC D10951as salt:D10952 ChEMBL363392as salt:ChEMBL17879 DTXSID701337104 Interactive image CCCCC1(CCCC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C1=CC=C(OCC2=CC=C(C[N+]34CCN(CC3)CC4)C=C2)C=C1)N(C)C InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1Key:STPKWKPURVSAJF-LJEWAXOPSA-N Maralixibat chloride, sold under the brand nameLivmarli, is amedicationused to treatcholestatic pruritusin people withAlagille syndrome.Maralixibat chloride is anileal bile acid transporter(IBAT) inhibitor. The most common side effects include diarrhea and abdominal pain (belly ache). Maralixibat chloride was approved for medical use in the United States in September 2021,and in the European Union in December 2022.